Screener / SEC EDGAR /CIK 0000037785 /10-K filed Feb 27, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Materials · Chemicals & Allied Products

FMC Corp FMC

Compare with peers Embed
SEC comment letters, last 20 years

2 reviews of FMC's filings by SEC staff

UPLOAD and CORRESP
Reviews 2 latest letter Oct 21, 2024
Questions asked 5 each answered in the company's own letter
No closing letter 0 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 2 UPLOAD
  2. 2. Questions in them 5 numbered comments
  3. 3. Company replies 2 CORRESP
  4. 4. Reviews closed 2 of 2 closing letter

Half the closed reviews took 27 days or less from the first letter to the closing letter.

FMC CORP · 10-K filed February 27, 2024 File No. 001-02376

2024-10-21 to 2024-11-05 · 2 questions · 1 letter from the SEC, 1 from the company
Review closed 2024-11-05
Non-GAAP measuresLiquidity and cash
Exhibit 99.1 · Second Quarter 2024 Highlights, page 1
SEC asked (1)
We note you present trends associated with the non-GAAP measures adjusted EBITDA and adjusted earnings per diluted share within the bullet points for the Second Quarter 2024 Highlights. Please also present the trends associated with consolidated GAAP net income and net income per diluted share. Refer to Question 102.10(a) of the Non-GAAP Financial Measures Compliance and Disclosure Interpretations.
FMC answered
In accordance with the Staff's comment, in our future filings including the bullet points in our Highlights on Exhibit 99.1, when a trend is included for a non-GAAP measure, we will include trends associated with the closest comparable GAAP measure. Specifically, trends associated with adjusted EBITDA and adjusted earnings per diluted share will be accompanied by trends for consolidated GAAP net income (loss) and net income (loss) per diluted share in our future filings.

Reconciliation of Net Income (loss) Attributable to FMC Stockholders (GAAP) To Return on Invested Capital, page 5
Read in the reply
Reconciliation of Net Income (loss) Atributable to FMC Stockholders (GAAP) To Return on · Invested Capital , page 5
SEC asked (2)
We note your calculation of ROIC uses a non-GAAP measure in the numerator. Please also present ROIC using net income (loss) attributable to FMC stockholders. Refer to Question 102.10(a) of the Compliance and Disclosure Interpretations for Non-GAAP Financial Measures.
Rest of the question

Form 10-Q for the Six Months Ended June 30, 2024 Free Cash Flow Reconciliation, page 47 Your free cash flow presentation includes a subtotal, adjusted cash flows from 3. operations, which excludes Project Focus transformation spending. The exclusion of this spending appears inconsistent with the guidance in Item 10(e)(1)(ii)(A) of Regulation S-K which prohibits excluding charges or liabilities that required or will require cash settlement from non-GAAP liquidity measures. Please advise or revise your presentation accordingly.

FMC answered
In accordance with the Staff's comment, in our future filings, we will include a row presenting return on invested capital (“ROIC”) calculated using the GAAP numerator in addition to the row calculating ROIC using the non-GAAP numerator within the reconciliation of net income (loss) attributable to FMC stockholders to ROIC in Exhibit 99.1.
Read in the reply

Also in this review: closing letter, 2024-11-05

Form 10-K for the fiscal year ended December 31, 2020

2021-09-23 to 2021-10-20 · 3 questions · 1 letter from the SEC, 1 from the company
Review closed 2021-10-20
Results discussion (MD&A)Liquidity and cashDebtRevenueNon-GAAP measures
After reviewing your response to these comments, we may have additional comments. Note 11: Debt, page 20
SEC asked (1)
We note the disclosure of the fourth amendment to the credit agreement entered into on May 26, 2021, which appears to have been entered into primarily to extend the termination date of the revolving credit facility to May 26, 2026.
Rest of the question

Given the remaining availability under the credit facility of $598.0 million at June 30, 2021 and that your debt maturities within one year are $1.19 billion, please tell us and confirm that in future filings you will more clearly disclose your plan for satisfying your debt obligations with your current and expected sources of liquidity. In this regard, based on your disclosure, it is not clear that you intend to access the option to increase the aggregate amount of the revolving credit commitments to $2.25 billion, which was provided for pursuant to the third amendment entered into on May 17, 2019.

FMC answered
In accordance with the Staff's comment, in our future filings within the debt footnote, we will clearly disclose our plan for satisfying our debt obligations with our current and expected sources of liquidity and will provide more clarity on our intent to utilize expansion options under our revolving credit facility.
Read in the reply
In its next report

First report after the company's reply of Oct 6, 2021: 10-Q filed Nov 3, 2021 ↗, against the 10-Q filed Aug 4, 2021 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Management's Discussion and Analysis, page 34 · Results of Operations, page 30
SEC asked (2)
Please tell us your consideration of disclosing a breakdown of revenue by each significant product and discussing the reason for changes in product revenue from period to period. In this regard we note on page 4 of the 10-K that Rynaxypyr and Cyazypyr actives represent over $1.8 billion in combined sales.
Rest of the question

You state in your earnings call for the second quarter 2021 that these products represent almost 40% of your sales. Refer to Item 303(a)(3)(i) of Regulation S-K.

FMC answered
Our portfolio is comprised of four product categories: insecticides, herbicides, and fungicides as well as a growing plant health business. Our decision to disclose revenue by each significant product category is based on the guidance pursuant to Accounting Standard Codification 606 (“606”). In our 2020 Form 10-K as well as our 2021 second quarter 10-Q, within Note 3: Revenue Recognition, we disaggregate revenue from contracts with customers by geographical areas and major product categories.

We believe the disaggregation of revenue into four product and four regional categories achieves the
Rest of the answer

disclosure objectives required by ASC 606-10-50-5. Specifically, we believe this provides the most meaningful presentation to depict how the nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factors. Additionally, we considered the guidance within ASC 606-10-55-90 which included an evaluation of (a) disclosures presented outside of the financial statements such as earnings releases and investor presentations, (b) information regularly reviewed by the Chief Operating Decision Maker and (c) other information that is used by the Company or users of the Company’s financial statements, to support this conclusion.

We consider the requirements of Item 303(a)(3)(i) of Regulation S-K when providing commentary on our revenue from contracts with customers. Specifically, we disclose within Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) whether the change in revenue during each period is driven by price, volume or foreign currency translation and we provide commentary at a geographical level to highlight the primary reasons for changes in revenue from period to period. In addition, we consider and disclose any significant components of revenues or expenses that, in our judgment, should be described in order to understand our results of operations.

Our insecticide product category is our largest revenue stream and features two key diamide-class molecules – Rynaxypyr® and Cyazypyr® active ingredients. We do not routinely present revenue by this subcategory on a quarterly basis or as a separate revenue stream within our external communications. The diamide portfolio represents a critical component of our product offerings, and accordingly, we provide additional commentary on our strategic initiatives to grow that portfolio within our annual report and on a less frequent basis, in our quarterly presentations including earnings calls. With respect to the guidance in ASC 606-10-50-5, we do not believe this subcategory consists of distinct differences from the broader insecticide product category as it relates to “nature, amount, timing and uncertainty”. Nevertheless, we would disclose any material period-to-period change in the composition of our revenues within any of our product categories as compared with any prior disclosure of such composition.

Read in the reply
In its next report

First report after the company's reply of Oct 6, 2021: 10-Q filed Nov 3, 2021 ↗, against the 10-Q filed Aug 4, 2021 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Management's Discussion and Analysis, page 34 · Results of Operations, page 30
SEC asked (3)
You discuss on page 30 of the 10-K and page 41 of the June 30, 2021 10-Q Adjusted EBITDA (Non-GAAP) without a similar discussion of the most comparable GAAP number preceding the discussion of the Non-GAAP measure. Please confirm you will revise the presentation throughout the filing in the future accordingly.
Rest of the question

In addition, confirm you will revise your reconciliations to start the reconciliation with the GAAP number included on your financial statements. For example, your presentation on page 35 of the 10-K and page 45 of the June 30, 2021 10-Q appear to reconcile from the Non-GAAP measures to the GAAP number. Refer to Question 102.10 of the Compliance and Disclosure Interpretations.

FMC answered
In accordance with the Staff's comment, in our future filings, we will include our discussion on Adjusted EBITDA, a non-GAAP measure, directly below our discussion of Net Income, the closest comparable GAAP measure, in the Results of Operations section of MD&A.

Additionally, in our future filings, we will revise the presentations that are noted on page 35 of the 10-K and page 45 of the June 30, 2021 10-Q to label the descriptions such that it is clear that our reconciliations start with the GAAP number.

* * * *

In connection with responding to your comments, we acknowledge that:

•We are
Rest of the answer

responsible for the adequacy and accuracy of the disclosure in our filings;

•Staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and

•We may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Read in the reply
In its next report

First report after the company's reply of Oct 6, 2021: 10-Q filed Nov 3, 2021 ↗, against the 10-Q filed Aug 4, 2021 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2021-10-20

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 6 letters filed since 2021-09-23. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/FMC/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.